Organic Active Ingredients TRIZ Cases

A 15%–30% moisture range helps all-white snus portions resist discoloration while preserving moistness, sensory characteristics, and controlled active-agent release.

Specific tricyclic molecular structures provide a route to inhibit mutant KRAS where effective treatment options remain limited.

Protected allylic alcohols reduce impurities in MCL-1 inhibitor synthesis, enabling cleaner scale-up without chromatography.

Charged polyester copolymers form polyplexes with biologics to improve delivery efficiency while reducing cytotoxicity and inflammatory response.

Thyroid hormone receptor beta agonists activate ABCD2 and VLCFA beta-oxidation to address X-ALD treatment limitations.

Dose reductions, blood-count monitoring, and G-CSF support help manage lurbinectedin-related hematological toxicity during SCLC treatment.

Pyrazolopyrimidine compounds target ALK2 and FGFR activity, expanding treatment options for cancer and anemia of chronic disease.

HDAC3 antagonists alter CD8+ T-cell epigenetic regulation to restore effector function and counter tumor-driven inactivation.

High-viscosity polymer in the capsule shell keeps trace amounts of tyndalized bacteria homogeneous and limits separation and sedimentation.

Cell-penetrating anti-DNA antibodies transport donor oligonucleotides into cells, increasing targeted editing frequency without nucleases or PNAs.

A dual-fluid irrigant mixes zinc or silver ions with chlorite at use to raise wound oxidation-reduction potential and sustain antimicrobial protection.

Real-time PCR targets IS481, IS1001, and hIS1001 to distinguish three Bordetella species and support faster treatment selection.

See how a formula (I) compound combined with lung surfactant targets inflammation and macrophage activity to address BPD and BPD-PH.

Oxidation can convert calcium channel-blocking 1,4-dihydropyridines into less active, more toxic pyridine analogues; chelating agents limit this degradation.

Taste-masking agents and suspending excipients create a palatable, homogeneous tasimelteon liquid for pediatric dosing.

Complementary oligonucleotides target LRRK2 RNA to reduce protein expression and address symptoms across Parkinson’s disease subtypes.

Cooling tissue before, during, and after capsaicin administration helps reduce transient burning while supporting extended joint pain relief.

Using template RNA, reverse transcriptase enables longer genetic sequence insertion into target cells while reducing DNA damage and interferon activation.

Controlled liquid-water hydration addresses cyclophosphamide moisture variability after freeze-drying, supporting storage stability and redissolving performance.

Aqueous dipeptide derivatives degrade enzymatically and resist sterilization; antioxidants, pH control, and lyophilization improve stability.

Varying molecular-weight polyglutamic acid compounds penetrate vaginal tissue layers to moisturize dryness without hormonal therapy.

Compound 1 targets TAAR1 and 5HT1A instead of D2 receptors to treat schizophrenia while reducing adverse events.

Selective pyrimidine ligands address poor A2A/A2B subtype selectivity while modulating immune responses in cancer and inflammatory disease.

A mixture of HCl and EDTANa4 helps stabilize LABA and corticosteroid pMDI formulations stored in aluminum cans.

Imidazolium-based cationic lipids in composite LNPs improve mRNA biodistribution and transfection for lung and spleen delivery.

Combination chemotherapy can raise normal-tissue toxicity; 5–50 nm EPR carriers concentrate conjugated drugs in tumors for controlled release.

Tertiary amine N-oxide lipids enable transcellular transport in liposomes, improving drug accumulation and penetration in target tissues.

Selective DHCR24 compounds address toxicity and specificity limits by increasing desmosterol for oral treatment of DHCR24-mediated disorders.

Electrospun PLGA and collagen scaffolds preload CHIR99021 to limit adipocyte infiltration and support muscle repair at the myotendinous junction.

Swelling, shaping, and adhesive materials control pirfenidone release for 24 hours, lowering peak-to-valley fluctuation for once-daily dosing.

Indazole compounds address T790M, L858R, and C797S EGFR resistance through selective inhibition of drug-resistant mutant kinases.

Aripiprazole raises NOXA and PUMA expression and promotes PARP cleavage to strengthen RAF inhibitor-induced cancer cell apoptosis.

GSTZ1 inhibitors block a resistance mediator and sensitize drug-refractory NSCLC cells to infigratinib or dasatinib.

Phosphorylated dihydroceramides modulate ceramidase activity to suppress oral cancer cells while sparing healthy tissue.

Formula (I) compounds preferentially inhibit persistent sodium current to reduce seizures while limiting toxicity linked to peak-current blockade.

Non-ionic surfactants and ester co-surfactants protect hydrolytically labile antipsychotics, limiting hydrolysis products below 50 ppm after 24 months.

An rAAV dose range of 5×10^13 to 1×10^15 genome copies/kg targets microdystrophin expression while managing immune-response risk.

Fisetin and quercetin elevate mitochondrial calcium to support chondrocyte function and help prevent cartilage degeneration.

An enteric core-shell tablet resists stomach acid, then disintegrates at intestinal pH for controlled delivery to targeted colon segments.

An HPMC-based ruxolitinib matrix maintains therapeutic plasma levels for up to 24 hours, reducing dosing frequency and harmful drug spikes.

Modular reaction steps and salt formation address AG-10 manufacturing limits while supporting yield, stability, and bioavailability.

Limited EPA/DHA protection against sea lice is addressed with a fish-diet supplement combining 22–30 wt.% Omega 3 and 8–20 wt.% Omega 7.

RALA peptide nanoparticles deliver coronavirus mRNA intracellularly while improving stability and supporting lyophilized vaccine storage.

RNAi constructs silence SCAP mRNA to reduce lipid synthesis and liver fat accumulation, addressing limited pharmacologic options for NAFLD.

Targeting ligands guide synthetic-backbone oligonucleotides toward selected cells, helping modulate genes while limiting off-target effects.

Combining ketamine and buprenorphine in a sublingual lozenge is presented as a way to accelerate treatment for opioid and alcohol addiction.

Intranasal delivery addresses oral metoclopramide's symptom burden in diabetic gastroparesis and lowers visits and hospitalizations.

Current arthritis treatments lack targeted ADAMTS inhibition; imidazolidine derivatives protect cartilage by inhibiting ADAMTS4 and ADAMTS5.

Existing treatments for DUX4 misexpression are ineffective; 2-aryl thiazole and benzothiazole compounds offer a new inhibition approach.

Lipid nanoparticles deliver EBV RNA antigens to address weak conventional vaccine responses and build neutralizing antibodies plus T-cell immunity.